The landscape of healthcare in the United Kingdom is undergoing a profound transformation, thanks to the integration of genomics into clinical practice. At this year’s Festival of Genomics and Biodata 2024, experts convened to discuss the groundbreaking advancements and promising future prospects of genomic medicine across various domains, including prenatal care, cancer treatment, population health, and pharmacogenomics.

Leading the Way: The Role of the NHS

The UK National Health Service (NHS) has emerged as a global leader in implementing genomics at scale and pace, building upon its contribution to initiatives like the 100,000 Genomes Project with the establishment of NHS Genomic Medicine. Through a network of genomic medicine hubs, the NHS has adopted a multi-professional and multi-regional approach, placing patients and the public at the centre of genomic healthcare delivery.

Advancements in Genomic Testing

The establishment of this national-level genomic medicine network has been facilitating standardised genomic testing for eligible patients for the past five years. Now, the focus is shifting from whole exome sequencing (WES) towards whole-genome sequencing (WGS) and evaluating the diagnostic yield of WGS, paving the way for further advancements in genomic diagnostics and personalised medicine. WGS covers the whole genome, not just the protein-coding exome, allowing for the detection of non-coding disease-causing variants. Rapid WGS has been rolled out for acutely unwell children and babies with a diagnostic yield of 43%. 3-4% of the individuals tested would not have received a diagnosis with whole exome sequencing.

Four Pillars of Genomic Strategy

The 2022 genomics strategy outlined 13 commitments across four pillars:

1. Embedding Genomics into the NHS: Efforts are underway to expand genomic services to the public while improving turnaround times. Initiatives include workforce profiling to identify additional skills needed and establishing ethics and advisory groups to facilitate public acceptance of health data sharing
2. Equitable Testing: Over 800,000 genomic tests have been conducted for cancer and rare diseases between 2021 and 2023, with a focus on driving precision treatments and enhancing test accessibility for those who need it.
3. Data and Digital Revolution:The transition from paper-driven systems to digitized, automated processes aims to streamline information management and sample tracking.
4. Research and Innovation: Genomic healthcare infrastructure is made accessible to researchers, fostering collaborations, and supporting the adoption of cutting-edge technologies in clinical practice.

Transformative Research Initiatives

Genomics England works to implement an “Infinity Loop” which links the goals of accelerating genomic research and evolving genomic healthcare. They store the data of over 150,000 genomes to facilitate the WGS element expansion of the NHS Genomics Programme. The reciprocal relationship between both organisations allows for patients undergoing testing to provide samples for research, allowing for a cyclical link between research and clinical care.

Various research initiatives are driving advancements in the alignment of research and genomic medicine:

• The Cancer 2.0 Initiative focuses on providing evidence to inform future policies. Pilot studies are underway with long-read sequencing platforms, with robust pipelines developed to facilitate their use on a research basis. The use of such platforms in laboratory hubs aims to inform NHS policy on future use of the systems in clinical settings. The programme aims to be multimodal, incorporating imaging data alongside genomic and clinical data, and to address the inequity in representation and diversity in genomics by sequencing 15,000 genomes of people with diverse backgrounds.
• The Generation Study, also referred to as the Newborn Genomes Programme, aims to sequence the genomes of newborns to diagnose treatable conditions early, as early intervention is key for positive health outcomes.

Collaboration and Integration Across Nations

Collaboration between the four nations of the UK is crucial for the success of genomic medicine. England, Scotland, Wales, and Northern Ireland each have unique approaches to genomic healthcare delivery, emphasizing the need for closer collaboration and unified approach to ensure equitable access and efficient data handling.

Our Future Health is a programme currently running across the UK that is unique in scale and diversity, aiming to recruit 5 million volunteers across the four nations. It is a collaboration between the public, charity and private sectors to build the UK’s largest health research programme. It will use volunteer blood samples and other health indicators to build a comprehensive database of genome data and health parameters to analyse complex variants and their link to disease, paving the way for early intervention and treatment in future generations.

Challenges and Future Directions

Despite significant progress, challenges remain, including the need for effective data sharing, workforce training, and addressing disparities in access to genomic healthcare. Moving forward, efforts will focus on integrating genomic data into electronic health records, expanding research initiatives, and implementing recommendations from key reports like the Lord O’Shaughnessy review, which emphasised the need for more rapid translation from clinical trials to wider clinical access.

Conclusion

The integration of genomics into healthcare is revolutionising patient care and treatment strategies in the UK. With ongoing advancements in technology, research, and collaboration, genomic medicine holds the promise of delivering personalised, precision healthcare to all, paving the way for a healthier and more equitable future.